Most Recent Funding
$14 Million Series A on July 15, 2013
Founded:
2012
Headquarters:
San Francisco, CA
Description:
Amphivena Therapeutics, a subsidiary of Affimed Therapeutics, develops treatments to address hematologic malignancies.
Categories:
Biotechnology

Detailed Description

Update

Amphivena Therapeutics Inc., a newly created subsidiary of venture-backed Affimed Therapeutics AG , has raised $14 million in Series A financing and has granted Janssen Biotech an exclusive option to acquire the company.

Affimed has used its TandAb technology to develop a pipeline of treatments for diseases such as Hodgkin lymphoma and non-Hodgkin lymphoma. Its new subsidiary, Amphivena, will use this technology to address hematologic malignancies, but specifics about its drug program and the indications it will pursue haven't been disclosed....

Funding Rounds (1) - $14M

Update

Offices/Locations (1)

Update
  • Office

    45 JUNIPER STREET

    San Francisco, CA 94103

    USA